Match
|
Document |
Document Title |
|
US20140310828 |
TARGETED MODIFICATION OF RAT GENOME
Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as... |
|
US20110021605 |
MEANS AND METHODS FOR THE SPECIFIC INHIBITION OF GENES IN CELLS AND TISSUE OF THE CNS AND/OR EYE
Described is a method for the specific modulation of the expression of target genes in cells and/or tissues of the CNS and/or eye, wherein a composition comprising one or more doubled stranded... |
|
US20100071079 |
METHODS FOR TREATING AUTOIMMUNE AND CHRONIC INFLAMMATORY CONDITIONS USING ANTAGONISTS OF CD30 OR CD30L
The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of... |
|
US20090035217 |
Truncated Fragments of Alpha-Synuclein in Lewy Body Disease
The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of... |
|
US20150366175 |
HUMANIZED IL-15 ANIMALS
Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or... |
|
US20130333058 |
Pluripotent Cells From Rat and Other Species
Pluripotent cells are derived and maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and an antagonist of an FGF receptor. |
|
US20110197290 |
METHODS AND MATERIALS FOR PRODUCING TRANSGENIC ARTIODACTYLS
Swine animal models comprising a genomic disruption of an endogenous gene chosen from the group consisting of a Low-Density Lipoprotein Receptor gene LDLR, Duchene's Muscular Dystrophy (DMD) gene,... |
|
US20080213259 |
Methods for Treating Autoimmune and Chronic Inflammatory Conditions Using Antagonists of CD30 or CD30L
The invention provides methods of treating autoimmnune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of... |
|
US20140182003 |
ANIMAL MODELS AND THERAPEUTIC MOLECULES
The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof... |
|
US20140072580 |
NOVEL TARGETS FOR TREATMENT OF HYPERCHOLESTEROLEMIA
In certain embodiments this invention this invention pertains to the discovery that inhibition of myosin light chain interacting protein (Mylip) can mitigate one or more symptoms of... |
|
US20120240245 |
Methods and compositions for detecting and treating retinal diseases
The invention discloses multiple genes related to age-related macular degeneration (AMD) and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD... |
|
US20130227717 |
HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this... |
|
US20110052500 |
TAJ in Neuronal Function
The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury,... |
|
US20100287630 |
MODELS FOR VACCINE ASSESSMENT
The present invention is directed to methods for constructing and using in vivo and in vitro models of aspects of human immunity and, in particular, construction of a human immune system model for... |
|
US20080260744 |
G PROTEIN COUPLED RECEPTORS AND USES THEREOF
The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are... |
|
US20150040249 |
Non-Human Animal Models of Depression and Methods of Use Thereof
The disclosure provides non-human optogenetic animal models of depression. Specifically, non-human animals each expresses a light-responsive opsin in a neuron of the animal are provided. The... |
|
US20140033334 |
TARGETED CELL DEATH
The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or... |
|
US20120225820 |
PEPTIDES ASSOCIATED WITH HLA-DR MHC CLASS II MOLECULE AND INVOLVED IN RHEUMATOID ARTHRITIS
Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an... |
|
US20110258713 |
COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION
The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular,... |
|
US20110119775 |
HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF
The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and... |
|
US20090007281 |
Animal Model for Assessing Copd-Related Diseases
Methods of diagnosis, markers, and screening techniques and animal models for assessing the severity and/or progression or regression of chronic obstructive pulmonary disease (COPD) and... |
|
US20080083041 |
Pre-Clinical Animal Testing Method
Devices and methods are provided for wirelessly powering and/or communicating with implanted medical devices used for the controlled exposure and release of reservoir contents, such as drugs or... |
|
US20130318648 |
DIAGNOSIS AND THERAPEUTIC EPITOPE, AND TRANSGENIC PLANT
A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope... |
|
US20050120398 |
Animal model for HCV infection
The present invention relates to a non-transgenic, non-human animal useful as a model for protease activity and for liver damage, including steatosis. |
|
US20090083867 |
Use of Antagonists of Cxcl13 or Cxcr5 for Treating Wounds of Fibrotic Diseases
The invention provides the use of an antagonist of CXCL 13 or CXCR5 activity in the preparation of a medicament for the prevention and/or inhibition of pathological scarring; as well as the use of... |
|
US20060053501 |
Method for detecting Nipah virus and method for providing immunoprotection against Henipa viruses
The present invention provides an animal model for monitoring Nipah virus infection, a method for the quantitative detection and rapid characterization of Nipah virus RNA in a sample, a... |
|
US20170071173 |
LINCRNA-DEFICIENT NON-HUMAN ANIMALS
Genetically modified non-human animals are provided that exhibit a functional lack of one or more lncRNAs. Methods and compositions for disrupting, deleting, and/or replacing lncRNA-encoding... |
|
US20140082758 |
Control and Characterization of Psychotic States
Provided herein are methods of inducing psychosis in animals using light-responsive opsins and methods of identifying or screening compounds that may be useful in treating psychosis. |
|
US20120073002 |
PREVENTION AND TREATMENT OF BLOOD COAGULATION-RELATED DISASES
Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental... |
|
US20120066779 |
HEPATITIS C RECEPTOR PROTEIN CD81
The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for... |
|
US20100169987 |
ANIMAL MODEL SIMULATING NEUROLOGIC DISEASE
The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having... |
|
US20060130161 |
Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes
Provided are non-human animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and autoimmune diseases such as diseases of the central nervous system, including... |
|
US20130097717 |
COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES
The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as fibroblast cells) into cardiomyocytes without introducing exogenous genes to the... |
|
US20140041063 |
Genetically Modified Rat Models for Obesity and Diabetes
This invention relates to a genetically modified or chimeric rat cell whose genome comprises chromosomal alleles of an obesity-diabetes gene (especially, the Mc4r gene or Lep gene), wherein at... |
|
US20090176773 |
Non-Peptidic Inhibitors of AKAP/PKA Interaction
The invention relates to non-peptidic molecules which modulate, especially inhibit, the interaction of protein kinase A (PKA) and A kinase anchor proteins (AKAP) and to a host or target organism... |
|
US20150052624 |
GENETICALLY MODIFIED RAT MODELS FOR PAIN
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered... |
|
US20160219845 |
G PROTEIN COUPLED RECEPTORS AND USES THEREOF
The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are... |
|
US20160174532 |
GENETICALLY MODIFIED RAT MODELS FOR PAIN
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered... |
|
US20140068794 |
R2R1/2 In Diagnosis and Therapy
The present invention stems from the finding that two genes designated R2R1 and R2R2, play important roles in tissue development and cancer biology. In particular, the inventors have discovered... |
|
US20110078804 |
Angiogenin and Amyotrophic Lateral Sclerosis
Methods and compositions for treating neurodegenerative disorders are provided. Transgenic animal models of neurodegenerative disorders are provided. Knockout animal models of neurodegenerative... |
|
US20090241205 |
METHOD FOR IDENTIFYING CRMP MODULATORS
The present invention refers to a method for identifying a modulator of CRMP suitable for the prevention, alleviation or/and treatment of CRMP-associated diseases. |
|
US20130227715 |
USE OF ENDONUCLEASES FOR INSERTING TRANSGENES INTO SAFE HARBOR LOCI
The present invention concerns the endonucleases capable of cleaving a target sequence located in a “safe harbor loci”, i.e. a loci allowing safe expression of a transgene. The present invention... |
|
US20100324114 |
Methods and kits to detect hereditary angioedema type III
The present invention relates to a method of diagnosing hereditary angioedema type III (HAE III) or a predisposition thereto in a subject being suspected of having developed or of having a... |
|
US20100056624 |
ANIMAL MODEL FOR PERIMENOPAUSE AND MENOPAUSE AND METHODS OF INDUCING OVARIAN FAILURE
The present invention relates to an animal model for human perimenopause and menopause. Also provided by the present invention are methods of making the animal model and methods of screening using... |
|
US20080255253 |
ANIMAL MODEL FOR PROSTATIC STROMAL HYPERPLASIA
The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia... |
|
US20130139273 |
Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression
A mouse model and uses there of for detecting, treating, characterizing, and diagnosing various diseases are described. |
|
US20070157324 |
HUMAN DISEASE MODELING USING SOMATIC GENE TRANSFER
This invention provides a system for modeling neurodegenerative and other diseases through somatic gene transfer. In addition, methods of multiple gene transfer, disease analysis and drug testing... |
|
US20050198696 |
Transgenic zebra fish embryo model for hematopoiesis and lymphoproliferative disorders
A transgenic zebrafish animal model for the study of haemopoietic cell differentiation, control, and screening of therapeutic agents. |
|
US20160033523 |
PHARMACOKINETIC ANIMAL MODEL
The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal... |
|
US20100132058 |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
Methods of treating somatosensory disorders and modulating production of proinflammatory cytokines by administering to a subject an effective amount of a COMT modulator, ADRB2 modulator, ADRB3... |